Early ReportRandomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Introduction
Toxic epidermal necrolysis (TEN) is a rare, acute, and life-threatening condition. The incidence is one case per million inhabitants per year.1 Apoptosis of cells causes erosions of the mucous membranes, extensive detachment of the epidermis, and severe constitutional symptoms. Cases with the most extensive skin detachment are associated with the poorer prognosis, and a 30–40% death rate. Milder forms are known as Stevens-Johnson syndrome (SJS) or SJS/TEN overlap.2 TEN is usually drug-related.3
At present there is no specific treatment for TEN. Some retrospective studies claimed a benefit of corticosteroids in milder forms,4 whereas several showed no benefit or even increased morbidity and mortality.5, 6, 7 Plasmapheresis, cyclosporin, cyclophosphamide, and N-acetylcysteine have been used in isolated cases and short uncontrolled series,8, 9, 10, 11 allowing no conclusion on the efficacy. Nevertheless, because the extent of final epidermal detachment is the main prognostic factor,12 therapies with the potential to stop the process of epithelial necrosis would be valuable during the initial phase of the disease.
Apoptosis is the mechanism of keratinocyte death in TEN, and tumour necrosis factor α (TNF-α) is the likely cause for this and for constitutional symptoms during TEN.10, 13 Thus, TNF-α production is believed to be an early pathogenetic event in TEN.
Thalidomide is a potent inhibitor of TNF-α in vitro and in vivo,14, 15 and appeared beneficial in several acute disorders thought to involve TNF-α.16, 17 We undertook a randomised placebo-controlled study of thalidomide in patients with TEN with the aim of testing the efficacy and safety of thalidomide in stopping the necrolysis process and reducing systemic symptoms during the initial phase of extension in TEN.
Section snippets
Patients
Patients were enrolled from nine centres representing recruitment of about half the cases of TEN in France. Patients over 18 years old were eligible if they had detachment of epidermis of more than 10% of body surface area,2 if the disease was still in the initial phase of extension and so had evolved for less than 4 days after the first mucocutaneous symptoms, and if they were expected to survive longer than 48 h. Diagnosis of TEN had to be confirmed with photographs and skin biopsy samples
Study population and clinical data
22 patients were enrolled in the study (figure 1) from May, 1995, to September, 1996. Of 15 patients at a single centre (Créteil), nine (60%) had died. This unusually high mortality rate alerted the local investigators. The trial coordinator was informed and decided to convene a safety board of three experts. The safety board first looked at the overall data without breaking the code—13 of 22 patients enrolled had died (overall mortality 59%). Because this rate was higher than expected from
Discussion
This study is the first double-blind, randomised, placebo-controlled trial of any therapy in TEN. Thalidomide was not effective in halting the necrolysis process during the initial phase of extension. On the contrary, thalidomide treatment was associated with increased mortality. This difference was not the result of an unexpectedly low rate of death in the placebo group, because the mortality rate in that group was of the same order in previous series.12, 20 The mortality remained
References (28)
- et al.
Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. Report of a patient treated with corticosteroid “pulse therapy”
J Am Acad Dermatol
(1985) - et al.
Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects
J Am Acad Dermatol
(1991) - et al.
Thalidomide as an anti-TNF-α inhibitor: implications for clinical use
Clin Immunol Immunopathol
(1996) - et al.
Enhancement of phorbol ester-induced production of tumor necrosis factor α by thalidomide
Biochem Biophys Res Commun
(1994) - et al.
Severe cutaneous adverse reactions to drugs
N Engl J Med
(1994) - et al.
A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme
Arch Dermatol
(1993) - et al.
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis
N Engl J Med
(1995) - et al.
Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids
Ann Surg
(1986) - et al.
Stevens-Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol
J Burn Care Rehabil
(1983) - et al.
Burn center care for patients with toxic epidermal necrolysis
J Am Coll Surg
(1995)
Plasmapheresis in severe drug-induced toxic epidermal necrolysis
Arch Dermatol
Toxic epidermal necrolysis treated with cyclosporin
Clin Exp Dermatol
Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis—treatment with N-acetylcysteine
Br J Dermatol
Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients
Arch Dermatol
Cited by (371)
The effects of systemic cyclosporine in acute Stevens-Johnson syndrome/toxic epidermal necrolysis on ocular disease
2021, Ocular SurfaceCitation Excerpt :Treatments attempted include systemic corticosteroids, intravenous immunoglobulin (IVIG), TNF-α inhibitors, and cyclosporine A (CsA). Though there is no clear consensus on effective systemic treatments, CsA has increasingly been shown to provide a mortality benefit in SJS/TEN [11–16]. CsA is a polypeptide that inhibits transcription of interleukin-2 (IL-2), and thus inhibits IL-2-driven infiltration of CD4+ and CD8+ T-cells and the activation of natural killer cells [17].
Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis
2020, Clinics in DermatologyOphthalmic Aspects of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Narrative Review
2023, Ophthalmology and Therapy